SER-155
Microbiome therapeutic
Evidence outlook · program status
On hold, for financing reasons
After advancing startup activities for the Phase 2 study, the company paused additional investment in the program as part of cost reduction actions while continuing to seek funding. Company Form 10-Q; approved in the freshness review queue. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04995653 NCT04995653 · Bacterial Infections in Allogeneic Stem Cell Transplant Registry: NCT04995653 | 1 | Safety and tolerability of SER-155, including incidence and severity of adverse events, serious adverse events, or adverse events of special interest (Day 100); Engraftment of SER-155 (Day 100) 2024-07-23 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Development is on hold (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.
2027 (1)
January 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent